Innovative Medical Devices Drive A Shift In China Medical Device Regulation Toward Active Guidance

Innovative medical devices drive a shift in China medical device regulation toward active guidance as the Center for Medical Device Evaluation (CMDE) of China’s National Medical Products Administration (NMPA) issues Notice No. 3 (2025) on March 26, 2025. The new policy moves away from a passive review model and adopts a proactive framework focused on early intervention, tailored enterprise strategies, end-to-end technical support, and coordinated review processes. These changes aim to accelerate market access for truly innovative technologies addressing urgent clinical needs.

Definition and Scope of Innovative Medical Devices

Innovative medical devices refer to medical equipment with novel features in design, technology, principles, or applications compared to existing products. Key characteristics include:

New Technical Principles: Operate on fundamentally different working principles from existing products.
New Application Fields: Expand existing technologies or their improvements to address unmet clinical needs.
Enhanced Efficacy or Safety: Demonstrate superior therapeutic outcomes or safety profiles compared to existing technologies.
Optimized Patient Experience: Reduce invasiveness, shorten recovery time, or lower complication risks.
Novel Design or Materials: Improve device performance or reduce costs through new materials or designs.
Digital and Intelligent Integration: Incorporate digital technologies (e.g., sensors, AI analytics) to enhance performance or interoperability.

Application Requirements, Conditions, and Process for Innovative Medical Devices

Application Conditions

Technological Innovation: Must demonstrate clear technological advancements (e.g., unique technical principles or functions) that improve diagnosis, treatment, or rehabilitation outcomes.
Safety and Efficacy: Requires validated clinical trial data and lab test results compliant with national standards.
Clinical Demand: Must address unmet clinical needs or elevate medical standards, supported by market research and scientific literature.
Originality: No identical products or technologies should exist globally; proven via patents or technical reports.

Application Requirements

Technical Documentation: Detailed design principles, manufacturing processes, and usage methods.
Clinical Trial Data: Scientifically rigorous data proving safety and efficacy, aligned with regulatory requirements.
Market Research Report: Analysis of market size, competitors, and growth potential.
Patent Certificates: Domestic and international patent filings/grants with technical descriptions and diagrams.
Technical Reports: Comprehensive documentation of device design, manufacturing, and applications.
Financial Proof: Evidence of funding capabilities (e.g., financial statements, investor commitments).

Review Process

Upon receipt of an application for special review of an innovative medical device, the Innovation Review Office will issue a review opinion within 60 working days (publicity and objection handling time are not counted). There is no change to the review requirements compared with the previous process. The main update is the formal availability of a pre-review mechanism for clinical trial protocols.

Pre-Review of Clinical Trial Protocols for Innovative Medical Devices

Concept

The pre-review of the clinical trial plan of innovative medical devices is equivalent to the pre-review, which will review the scientific nature of the clinical trial plan, the rationality of the trial design, the safety and effectiveness evaluation methods and other program contents, and put forward pre-review opinions. This will help ensure that the clinical trial design meets the requirements of NMPA, reduce the follow-up supplement, and accelerate the product registration process. For innovative medical device products, the applicant can apply for pre-review of the clinical trial protocol. CMDE will conduct a pre-review of the clinical trial protocol, and the feedback will be used as an important reference for the subsequent technical review process.

Pre-Review Authority

The Innovative Medical Device Review Office under CMDE conducts pre-reviews of application materials.

Key Expert Review Focuses

Data Integrity: Applicants must ensure submitted materials are truthful, accurate, complete, and traceable, bearing full legal responsibility.
Scientific Rigor: Protocols must reflect product characteristics, clinical risks, and pre-trial research data.

Post-Review Considerations

Compliance: Trials must strictly follow CMDE’s pre-review feedback.
Protocol Amendments: Any changes to product specifications or trial design require risk assessments and potential re-submission for pre-review.

Impact on Overseas Manufacturers

Resource Prioritization

NMPA/CMDE prioritizes review resources for clinically urgent innovative devices, significantly shortening market entry timelines for overseas manufacturers.

Policy Support Mechanisms

The “early intervention, tailored strategies, full-process guidance” approach provides:

Clear communication channels and advisory services.
Pre-review feedback during clinical trial design to reduce uncertainties.
Accelerated registration pathways for qualified innovations.

Further Information

To read the original CMDE of NMPA announcement about key changes to the regulatory framework for innovative medical devices, please click here.

If you are a medical device manufacturer with questions about how the new regulatory framework in China affects your product registration or clinical trial planning, please contact Cisema.